Peptide / GH Axis

IGF-DES (Des(1-3)IGF-1)

Truncated IGF-1 analogue — des(1-3) variant. 10× more potent than IGF-1 LR3 at the IGF-1 receptor due to reduced IGFBP binding. Extremely short half-life requiring immediate post-workout injection directly into the target muscle (intramuscular). Not systemic like IGF-1 LR3.

Build protocol outline Open dose calculator TNHL ebooks

Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.

Reference dose20–50 mcg IM into target muscle immediately post-workout

Half-life0.5 hours

Risk flaghigh

Regulatory noteResearch-only flag

Side effects and watch-outs

⚠️ Severe hypoglycaemia risk — inject within 30 mins of carbohydrate meal
⚠️ Localised muscle growth only (intramuscular injection site)
Must inject directly into target muscle — not SubQ
Short acting — very precise timing required
Jaw growth with systemic use
Organ growth risk at high doses
⚠️ Never use if active malignancy
Insulin-like effect — have fast carbs available at all times